FDA reviews TNX-102 SL for Fibromyalgia by August 2025, with no advisory required. See why we recommend a buy on TNXP stock.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has earned a consensus rating of “Moderate Buy” from the twenty ...

Too often, the disconnect between a company’s IT department and its business teams slows progress and leads to missed ...

Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC ...

As Robert F. Kennedy Jr. settles into his role as President Donald Trump’s health secretary, one major promise he’s made is ...

Cybercriminals’ tactics have evolved to target sensitive data and disrupt research and development in the pharmaceutical ...

The data to be presented encompasses five of the company’s novel drug candidates: BCR-ABL tyrosine kinase inhibitor olverembatinib (HQP1351), Bcl-2 inhibitor lisaftoclax (APG-2575), FAK/ALK/ROS1 ...

The pharmaceutical industry on Thursday blasted the UK government's levy that aims to curb the national health system's drugs ...

Walgreen Co., Kroger Co., and Albertsons Cos. Inc. accused two pharmaceutical companies Tuesday of conspiring to delay the generic version of a drug to treat gastroesophageal reflux disease and ...